MetaCap

Precision BioSciences (DTIL) vs Ocugen (OCGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Precision BioSciences (DTIL) has outperformed Ocugen (OCGN) over the past year, gaining 48.0% versus a loss of 33.8%. Over five years, OCGN leads with a -88.1% price change compared with -97.2% for DTIL. Precision BioSciences is the larger company by market cap ($282.5 million vs $260.6 million), about 1.1 times the size, while Ocugen is growing revenue faster (+8.8% vs -50.1%).

Precision BioSciences converts more of its revenue into profit, with a net margin of -133.4% versus -1537.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DTIL+48.00%OCGN-33.80%
+121%+37%-47%
Nov 21, 20251 yearNov 20, 2026
DTIL-97.36%OCGN-90.05%
+5%-49%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DTIL versus OCGN key metrics
MetricDTILOCGN
Share price$7.40$0.7679
Market cap$282.46M$260.55M
1-day change+7.09%+4.79%
YTD return+77.88%-43.12%
1-year return+48.00%-33.80%
5-year return-97.23%-88.09%
P/E ratio (TTM)29.60—
EPS (TTM)$0.25$-0.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$34.26M$4.41M
Revenue growth (YoY)-50.12%+8.83%
Net income (latest FY)$-45.72M$-67.85M
Operating margin-152.19%-1425.70%
Net margin-133.45%-1537.41%
52-week high$11.29$2.73
52-week low$3.53$0.691
Distance from 52-week high-34.46%-71.82%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+297.30%+1484.84%
Average volume319.79K7.34M
Shares outstanding38.17M339.31M
Employees69116
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DTIL has outperformed OCGN by 81.8 percentage points over the past year.
  • Precision BioSciences is more profitable, keeping -133.4 cents of every revenue dollar as net income versus -1537.4 cents for Ocugen.
  • Ocugen grew revenue faster in its latest fiscal year (+8.83% vs -50.12%).

About Precision BioSciences

DTIL stock →

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 69 employees

About Ocugen

OCGN stock →

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 116 employees

DTIL vs OCGN FAQ

Which is bigger, Precision BioSciences or Ocugen?

Precision BioSciences (DTIL) is larger, with a market capitalization of $282.46M compared with $260.55M for Ocugen (OCGN).

Which stock has performed better over the past year, DTIL or OCGN?

DTIL returned +48.00% over the past 12 months, compared with -33.80% for OCGN (price return, excluding dividends). Past performance does not predict future results.

Are Precision BioSciences and Ocugen in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons